glp 1 pancreatic cancer risk 🩺 Could Weight Loss Drugs Be a Secret Weapon Against Cancer? Could Weight Loss Drugs Be a Secret Weapon Against Cancer? 💡 Why it matters: This shifts the narrative of GLP-1s from OR | Early GLP-1 Agonist

Archived from the original on 11 November 2014

As GLP-1 receptor agonists (GLP-1s) like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) become increasingly common in the treatment of diabetes, obesity, and cardiovascular disease, retina specialists are paying close attention to whether the drug therapies may influence ocular disease in already high-risk patients

Around 98% of the body's L-Carnitine stores are found in skeletal muscle, with smaller amounts present in the heart and brain

While the exact cause of this potential link is not clear, the type of rapid weight loss that often accompanies the use of Ozempic can trigger hair loss

Three mechanisms drive semaglutide-related muscle loss: Reduced caloric intake